Barak Pharmaceutical Private Limited
Pharmaceutical trading company incorporated in 2017, based in Mumbai, Maharashtra.
2017 | Mumbai, Maharashtra (India) | Active
Barak Pharmaceutical Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2020
- Open Charges ₹ 0.50 M
- Revenue Growth -90.05%
- Profit Growth -91.66%
- Ebitda -372.87%
- Net Worth 2.62%
- Total Assets 995.74%
About Barak Pharmaceutical
Barak Pharmaceutical Private Limited (BPPL) is a Private Limited Indian Non-Government Company incorporated in India on 27 October 2017 (Seven years and four months 3 days old ). Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹0.50 M.
Dinesh Sahare and Nisha Dinesh serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U74999MH2017PTC301240
- Company No.
301240
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Oct 2017
- Date of AGM
31 Dec 2020
- Date of Balance Sheet
31 Mar 2020
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Pharma
Who are the key members and board of directors at Barak Pharmaceutical?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dinesh Sahare  | Director | 27-Oct-2017 | Current |
| Nisha Dinesh | Director | 17-Jun-2019 | Current |
Financial Performance of Barak Pharmaceutical.
Barak Pharmaceutical Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 90.05% decrease. The company also saw a substantial fall in profitability, with a 91.66% decrease in profit. The company's net worth moved up by a moderate rise of 2.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Barak Pharmaceutical?
In 2019, Barak Pharmaceutical had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
Open Charges
₹0.50 M
Satisfied Charges
₹0
Charges Breakdown by Lending Institutions
- Others : 0.05 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 20 Mar 2019 | Others | ₹0.50 M | Open |
How Many Employees Work at Barak Pharmaceutical?
Unlock and access historical data on people associated with Barak Pharmaceutical, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Barak Pharmaceutical, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Barak Pharmaceutical's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
